Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cp-724714. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 known ✓ | P04626 | 17/20 | 1.00 |
| ▸ | EGFR | P00533 | 10/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | CDK8 | P49336 | 1/20 | 1.00 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 1.00 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 1.00 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.50 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp-724714 SCHEMBL4617807 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL29561705 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL30450143 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL4796165 | 1.00 | ERBB2 (1.00) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6169707 | 0.99 | ERBB2 (0.98) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6169715 | 0.99 | ERBB2 (0.98) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168343 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168355 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168480 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 | |
| Cp-724714 SCHEMBL6168463 | 0.97 | ERBB2 (0.94) | ERBB2EGFRFECHCDK8MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 901 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3303610-B1 | COMPOSITIONS AND METHODS FOR SCREENING SOLID TUMORS | QUEST DIAGNOSTICS INVEST INC (US) | 2024-05-08 | — | — | EP | claimed |
| WO-2014179528-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS INCLUDING SUBSTITUTED NAPHTHALIMIDES SUCH AS AMONAFIDE FOR THE TREATMENT OF IMMUNOLOGICAL, METABOLIC, INFECTIOUS, AND BENIGN OR NEOPLASTIC HYPERPROLIFERATIVE DISEASE CONDITIONS | BROWN DENNIS M (US) | 2014-11-06 | — | — | WO | claimed |
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | FRIZER INC. | 2008-08-14 | — | — | US | claimed |
| EP-1896030-A1 | COMBINATIONS OF ERBB2 INHIBITORS WITH OTHER THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER | Pfizer Products Incorporated (US) | 2008-03-12 | — | — | EP | claimed |
| EP-1448551-B1 | PROCESSES FOR THE PREPARATION OF SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | OSI PHARM INC (US) | 2007-10-31 | — | — | EP | claimed |
| EP-1740184-A1 | COMBINATIONS OF SIGNAL TRANSDUCTION INHIBITORS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | claimed |
| WO-2006129163-A1 | COMBINATIONS OF ERBB2 INHIBITORS WITH OTHER THERAPEUTIC AGENTS IN THE TREATMENT OF CANCER | PFIZER PRODUCTS INC. (US) | 2006-12-07 | — | — | WO | claimed |
| EP-1720858-A1 | CRYSTAL FORMS OF E-2-METHOXY-N-(3-{4- [3-METHYL-4-(6-METHYL-PYRIDIN-3-YLOXY)-PHENYLAMINO -QUINAZOLIN-6-YL}-ALLYL)-ACETAMIDE | Pfizer Products Incorporated (US) | 2006-11-15 | — | — | EP | claimed |
| EP-1682176-A1 | SELECTIVE ERBB2 INHIBITOR/ANTI-ERBB ANTIBODY COMBINATIONS IN THE TREATMENT OF CANCER | Pfizer Products Inc. (US) | 2006-07-26 | — | — | EP | claimed |
| EP-1658080-A1 | DOSING SCHEDULE FOR A ERBB2 ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| WO-2004089934-A1 | PROCESSES FOR THE PREPARATION OF N-((((PYRIDINYLOXY) -PHENYLAMINO) QUINAZOLINYL)- ALLYL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS WELL AS INTERMEDIATES OF SUCH PROCESSES AND PROCESSES FOR THE PREPARATION OF SUCH INTERMEDIATES | PFIZER PRODUCTS INC. (US) | 2004-10-21 | — | — | WO | claimed |
| EP-1456199-A1 | SALT FORMS OF E-2-METHOXY-N-(3-(4-(3-METHYL-PYRIDIN-3-YLOXY)-PHENYLAMINO)-QUINAZOLIN-6-YL)-ALLYL)-ACETAMIDE, ITS PREPARATION AND ITS USE AGAINST CANCER | Pfizer Products Inc. (US) | 2004-09-15 | — | — | EP | claimed |
| WO-2004056802-A1 | COMPLEXES OF E-2-METHOXY-N-(3-{4-[3-METHYL-4-(6-METHYL-PYRIDIN-3-YLOXY)-PHENYLAMINO]-QUINAZOLIN-6-YL}-ALLYL)-ACETAMIDE, THEIR METHOD OF PRODUCTION, AND USE | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| US-20030171386-A1 | Small molecules for the treatment of abnormal cell growth | PFIZER INC. | 2003-09-11 | — | — | US | claimed |
| US-20030158217-A1 | Salt forms of E-2-Methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production | PFIZER INC. | 2003-08-21 | — | — | US | claimed |
| US-20030144506-A1 | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC. | 2003-07-31 | — | — | US | claimed |
| WO-2003050108-A1 | SALT FORMS OF E-2-METHOXY-N-(3-(4-(3-METHYL-PYRIDIN-3-YLOXY)-PHENYLAMINO)-QUINAZOLIN-6-YL)-ALLYL)-ACETAMIDE, ITS PREPARATION AND ITS USE AGAINST CANCER | PFIZER PRODUCTS INC. (US) | 2003-06-19 | — | — | WO | claimed |
| EP-1292591-A2 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | claimed |
| WO-2001098277-A2 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2001-12-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | ERBB2 755/4885EGFR 119/4885FECH 3297/4885 |
| US-20030158217-A1 | Salt forms of E-2-Methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production | ME2, ME3, SDHB | ERBB2 2026/4885EGFR 1009/4885FECH 1396/4885 |
| US-20080194596-A1 | Therapeutic Combination Including a Selective Erbb2 Inhibitor | ERBB2, ERBB3, EGFR | ERBB2 1/4885EGFR 3/4885FECH 3926/4885 |
| US-20030171386-A1 | Small molecules for the treatment of abnormal cell growth | ERBB2, EGFR, ERBB3 | ERBB2 1/4885EGFR 2/4885FECH 4706/4885 |
| US-20030144506-A1 | Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNE1, CCNT1 | ERBB2 1149/4885EGFR 148/4885FECH 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.